Making cancer treatment more accessible


Accessible treatment: If we can classify the patients into those who don’t need chemotherapy and those who need chemotherapy, that will save money, says Dr Devanand.

THE biosimilar version of the breast cancer drug trastuzumab was approved by the United States Food and Drug Administration (FDA) in December. Not long after, neighbouring Thailand also registered the drug.

But the Malaysian authorities are dragging their feet in registering the the drug, which could bring some hope to patients who wanted the targeted drug therapy.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Health , Business , drugs , patent

   

Next In Nation

KKB by-election: Nomination day preparations 90% complete
Your questions on the EPF account restructuring answered
Fuel station owner fined RM30,000 for selling RON95 to foreign-registered vehicle
Selangor Sultan attends religious ceremony at Lumut naval base
Man nabbed in KL for ramming car into another vehicle
Najib had a chance to defend himself when giving statement, MACC officer tells court
Malaysia’s 5G adoption rate almost 36%, coverage 80.3%, says Fahmi
Stakeholders to take action on casino licence report, says Anwar
Past mistakes should serve as lesson to save Malaysia Airlines, says Anwar
E-Filing: Deadline to submit tax return forms for non-business taxpayers extended to May 15

Others Also Read